ArticleRSC medicinal chemistry2025
Lactose-conjugated 2-iminothiazolidin-4-ones: synthesis, inhibitory activity and molecular simulations as potential inhibitors against enzymes responsible for type 2 diabetes.
Article in RSC medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of new substituted lactose-conjugated 2-iminothiazolidin-4-ones 7a-h were synthesized and scanned for their inhibitory activity against enzymes responsible for type 2 diabetes, including α-amylase, α-glucosidase, DPP-4, and PTP1B. Three lactose-conjugated 2-iminothiazolidin-4-ones 7c, 7e, and 7f exhibited the highest inhibitory activity against the selected enzymes. Compounds 7c and 7e were the strongest inhibitors for DPP-4 and α-amylase, respectively, whereas 7f exhibited strong inhibition against α-glucosidase and PTP1B. These compounds had also high anti-glycation and antioxidant activities and were not cytotoxic to the WI-38 cell line. A molecular docking study was applied to the three most potent inhibitors 7c, 7e, and 7f in inhibition against enzymes 1OSE, 3TOP, 3W2T, and 1NNY. These ligands had active interactions with the residues in the catalytic pocket of these enzymes consistent with their inhibitory efficacy against each enzyme tested. Molecular dynamics simulations were applied for four typical complexes 7e/1OSE, 7f/3TOP, 7c/3W2T, and 7f/1NNY to validate the obtained
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.